IN8bio presents new preclinical data from INB-619

IN8bio (INAB) presented new preclinical data from its gammadelta T cell engager program, INB-619, at the 2025 American College of Rheumatology, ACR, Convergence Meeting in Chicago. In preclinical SLE donor models, INB-619 achieved complete elimination of B cells with efficacy equivalent to approved CD19 and CD20 engagers, including the FDA-approved compounds blinatumomab and mosunetuzumab. The data demonstrated minimal secretion of adverse cytokines such as IL-6, a validated biomarker for cytokine release syndrome, CRS, at concentrations multiples lower than the currently marketed compounds tested.